Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
By Maggie Fick and Robin Respaut LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information ...
Read moreDetailsTag: Novo Nordisk
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
(Reuters) - Eli Lilly (LLY) and Hong Kong-listed Laekna (2105.HK) will collaborate to develop an experimental obesity drug that aims ...
Read moreDetails
